ABEO - Abeona Therapeutics Inc.
| Previous Close | 8.18 |
| Open | 8.20 |
| Bid | 7.64 x 800 |
| Ask | 8.50 x 1300 |
| Day's Range | 7.90 - 8.40 |
| 52 Week Range | 6.26 - 22.00 |
| Volume | 978,141 |
| Avg. Volume | 401,698 |
| Market Cap | 382.819M |
| Beta (3Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.63 |
- Simply Wall St.•6 days ago
Is Abeona Therapeutics's (NASDAQ:ABEO) 173% Share Price Increase Well Justified?
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But in contrast you can make much more than 100% if the company does well. To wit, the Abeona...
- GlobeNewswire•7 days ago
Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
NEW YORK and CLEVELAND, April 15, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data.
- GlobeNewswire•18 days ago
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in cell and gene therapy development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABO-101, the Company’s novel one-time gene therapy for Sanfilippo syndrome type B (MPS IIIB). ABO-101 is designed to deliver a functional copy of the NAGLU gene to the central nervous system and peripheral tissues.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ABEO earnings conference call or presentation 19-Mar-19 2:00pm GMT
Q4 2018 Abeona Therapeutics Inc Earnings Call
Motley Fool•last monthAbeona Therapeutics Inc (ABEO) Q4 2018 Earnings Conference Call Transcript
ABEO earnings call for the period ending December 31, 2018.
- Associated Press•last month
Abeona Therapeutics: 4Q Earnings Snapshot
On a per-share basis, the Dallas-based company said it had a loss of 36 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. “The diligent work conducted over the past nine months at our GMP manufacturing facility puts us on track to initiate the pivotal VITAL™ study evaluating EB-101, our gene-corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa, in mid-2019.
- Simply Wall St.•2 months ago
What Investors Should Know About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Financial Strength
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Zero-debt allows substantial financial flexibility, especially for small-cap companies likeRead More...
- GlobeNewswire•2 months ago
Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference
NEW YORK and CLEVELAND, Feb. 22, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies.
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced the appointment of João Siffert, M.D. as Chief Executive Officer (CEO), effective immediately. Dr. Siffert joined Abeona as Head of Research & Development (R&D) and Chief Medical Officer (CMO) in 2018, and has served as interim CEO since November of last year.
- ACCESSWIRE•3 months ago
The Unknown Biotech Play that Could Deliver 400% Returns, or Much More
The market for cell therapies of all kinds is exploding in size. Orgenesis Inc (ORGS) is making a name for itself as a top-notch provider of manufacturing to cell therapy drug developers. The company's revenue is growing consistently, and they recently achieved a key milestone under a 2018 investment agreement from a leading healthcare investment groups in the U.S., Great Point Partners.
- GlobeNewswire•3 months ago
Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
NEW YORK and CLEVELAND, Jan. 31, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene.
- GlobeNewswire•3 months ago
Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that it has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer.
- Simply Wall St.•4 months ago
How Should Investors Feel About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) CEO Pay?
Tim Miller has been the CEO of Abeona Therapeutics Inc. (NASDAQ:ABEO) since 2015. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
- Insider Monkey•4 months ago
Is Abeona Therapeutics Inc (ABEO) A Good Stock To Buy?
“Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
- Zacks•4 months ago
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Zacks•4 months ago
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- GlobeNewswire•5 months ago
Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS.
- Zacks•5 months ago
Moving Average Crossover Alert: Abeona Therapeutics
Abeona Therapeutics Inc. (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- GlobeNewswire•5 months ago
Abeona Therapeutics to Host R&D Day on December 6, 2018
NEW YORK and CLEVELAND, Nov. 29, 2018 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and.
- GlobeNewswire•5 months ago
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•5 months ago
Abeona Therapeutics Announces CEO Transition
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the immediate termination of its Chief Executive Officer, Dr. Carsten Thiel due to personal misconduct that violated the Company’s Code of Business Conduct and Ethics.
- GlobeNewswire•5 months ago
Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference
NEW YORK and CLEVELAND, Nov. 13, 2018 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of ABEO earnings conference call or presentation 12-Nov-18 3:00pm GMT
Q3 2018 Abeona Therapeutics Inc Earnings Call
